Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557859 | 0.83 | HDAC1 (0.38) | ACHEHDAC1HDAC2HDAC6BCHE | |
| SCHEMBL557865 | 0.83 | HDAC1 (0.38) | ACHEHDAC1HDAC2HDAC6BCHE | |
| SCHEMBL558113 | 0.83 | HDAC1 (0.38) | ACHEHDAC1HDAC2HDAC6BCHE | |
| SCHEMBL557472 | 0.83 | HDAC1 (0.38) | ACHEHDAC1HDAC2HDAC6BCHE | |
| SCHEMBL10099760 | 0.82 | ACHE (0.45) | ACHEHDAC1HDAC2HDAC6BCHE | |
| SCHEMBL557648 | 0.82 | SLC7A5 (0.35) | ACHEHDAC1BCHE | |
| SCHEMBL557905 | 0.81 | TSHR (0.35) | HTR4ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL2531573 | 0.78 | HDAC1 (0.35) | HDAC1HDAC2HDAC6KMT2ASMN1; SMN2 | |
| SCHEMBL558856 | 0.75 | HDAC1 (0.34) | HDAC1HDAC2HDAC6KMT2ASMN1; SMN2 | |
| SCHEMBL18116191 | 0.74 | HDAC1 (0.35) | ACHEHDAC1HDAC2HDAC6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | ACHE 4746/4885HTR4 3448/4885HDAC1 1440/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | ACHE 4760/4885HTR4 3491/4885HDAC1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.